Pacific Edge Limited (ASX:PEB)
Pacific Edge Limited (ASX:PEB) is a cancer diagnostics company specialising in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.
Pacific Edge's products are built from its proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.
The Company is currently focused on bladder cancer products however its intellectual property also covers the areas of gastric, colorectal and endometrial cancers and melanoma all of which is expected to provide the Company with further growth options in the future.
Pacific Edge operates a franchise-like business model, which includes wholly owned subsidiaries and licensed partners.
The Company has targeted specific geographies and markets where it expects its products can be readily adopted at scale.
Pacific Edge Limited is also listed on the New Zealand Stock Exchange (NZX:PEB).